GENB (GENB)
12.90
+0.34 (2.71%)
Upcoming Events
Latest Headlines
AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
October 14, 2026 9:45 AM - StreetInsider
Generate Biomedicines and Zealand Pharma strike AI drug deal
October 13, 2026 4:30 PM - StreetInsider
Zealand Pharma and Generate Biomedicines strike AI drug deal
October 13, 2026 4:30 PM - StreetInsider
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
October 13, 2026 4:30 PM - StreetInsider
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
October 13, 2026 4:30 PM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Generate Biomedicines (GENB)
October 5, 2026 6:41 AM - StreetInsider
Roswell Park begins first human trial of AI-designed CAR T therapy
October 1, 2026 7:03 AM - StreetInsider
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
October 1, 2026 7:00 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Generate Biomedicines (GENB)
September 9, 2026 7:28 AM - StreetInsider
Generate Biomedicines Inc. to Participate in September Investor Conferences
September 8, 2026 7:09 AM - StreetInsider
Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
September 1, 2026 9:07 AM - StreetInsider
Generate Biomedicines (GENB) PT Raised to $30 at H.C. Wainwright
August 28, 2026 7:04 AM - StreetInsider
Form 8-K Generate Biomedicines, For: Aug 25
August 26, 2026 6:03 AM - SEC Filing
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026 7:00 AM - StreetInsider
Form 8-K Generate Biomedicines, For: Aug 06
August 6, 2026 6:08 AM - SEC Filing
Form 10-Q Generate Biomedicines, For: Jun 30
August 6, 2026 6:08 AM - SEC Filing
Full Article List
